Halothane potentiates the effect of methamphetamine and nomifensine on extracellular dopamine levels in rat striatum

A microdialysis study

Y. U. Adachi, K. Watanabe, T. Satoh, E. Vízi

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Brain microdialysis was used to study the in vivo release and metabolism of dopamine (DA) in the rat striatum during halothane anaesthesia. Concentrations were measured in microdialysates collected every 20 min and applied directly to an on-line high-performance liquid chromatograph. Halothane was administered at concentrations of 0.5, 1.0, 1.5 and 2.0%. In another series of experiments, rats were treated intraperitoneally or locally with methamphetamine, a drug of abuse, or with nomifensine, a dopamine uptake blocker and antidepressant, in combination with 0.5 or 1.5% halothane. Halothane anaesthesia did not affect the dialysate (extracellular) concentration of DA at 2.0%. By contrast, the concentrations of DA metabolites [3-methoxytyramine (3-MT), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA)] increased during inhaled halothane anaesthesia in a dose-dependent manner and recovered after anaesthesia. Halothane potentiated the ability of methamphetamine to increase the extracellular concentration of DA when administered systemically, whereas only a small increase in DA accumulation was seen when methamphetamine was administered locally via the perfusate. Similarly, the increase in extracellular DA was accentuated by systemic nomifensine during halothane anaesthesia, but no obvious enhancement was observed when it was applied locally. It has been shown that the neurotoxic effect of methamphetamine is mediated by the suboxidation of DA released from the cytoplasm into the extracellular space and transformed into highly reactive free radicals. On the basis of our results, it is suggested that care should be exercised when halothane anaesthesia is used in patients abusing phenylethylamines (amphetamines) or being treated with DA uptake blockers (nomifensine).

Original languageEnglish
Pages (from-to)837-845
Number of pages9
JournalBritish Journal of Anaesthesia
Volume86
Issue number6
DOIs
Publication statusPublished - 2001

Fingerprint

Nomifensine
Methamphetamine
Microdialysis
Halothane
Dopamine
Anesthesia
Dopamine Antagonists
Phenethylamines
Amphetamines
3,4-Dihydroxyphenylacetic Acid
Homovanillic Acid
Dialysis Solutions
Extracellular Space
Street Drugs
Antidepressive Agents
Free Radicals
Cytoplasm

Keywords

  • Anaesthetics volatile, halothane
  • Analeptics, methamphetamine
  • Ataractics, nomifensine
  • Brain striatum
  • Brain, dopamine release

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Halothane potentiates the effect of methamphetamine and nomifensine on extracellular dopamine levels in rat striatum : A microdialysis study. / Adachi, Y. U.; Watanabe, K.; Satoh, T.; Vízi, E.

In: British Journal of Anaesthesia, Vol. 86, No. 6, 2001, p. 837-845.

Research output: Contribution to journalArticle

@article{2e9ffee6dadd4d589d252fdc175b4940,
title = "Halothane potentiates the effect of methamphetamine and nomifensine on extracellular dopamine levels in rat striatum: A microdialysis study",
abstract = "Brain microdialysis was used to study the in vivo release and metabolism of dopamine (DA) in the rat striatum during halothane anaesthesia. Concentrations were measured in microdialysates collected every 20 min and applied directly to an on-line high-performance liquid chromatograph. Halothane was administered at concentrations of 0.5, 1.0, 1.5 and 2.0{\%}. In another series of experiments, rats were treated intraperitoneally or locally with methamphetamine, a drug of abuse, or with nomifensine, a dopamine uptake blocker and antidepressant, in combination with 0.5 or 1.5{\%} halothane. Halothane anaesthesia did not affect the dialysate (extracellular) concentration of DA at 2.0{\%}. By contrast, the concentrations of DA metabolites [3-methoxytyramine (3-MT), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA)] increased during inhaled halothane anaesthesia in a dose-dependent manner and recovered after anaesthesia. Halothane potentiated the ability of methamphetamine to increase the extracellular concentration of DA when administered systemically, whereas only a small increase in DA accumulation was seen when methamphetamine was administered locally via the perfusate. Similarly, the increase in extracellular DA was accentuated by systemic nomifensine during halothane anaesthesia, but no obvious enhancement was observed when it was applied locally. It has been shown that the neurotoxic effect of methamphetamine is mediated by the suboxidation of DA released from the cytoplasm into the extracellular space and transformed into highly reactive free radicals. On the basis of our results, it is suggested that care should be exercised when halothane anaesthesia is used in patients abusing phenylethylamines (amphetamines) or being treated with DA uptake blockers (nomifensine).",
keywords = "Anaesthetics volatile, halothane, Analeptics, methamphetamine, Ataractics, nomifensine, Brain striatum, Brain, dopamine release",
author = "Adachi, {Y. U.} and K. Watanabe and T. Satoh and E. V{\'i}zi",
year = "2001",
doi = "10.1093/bja/86.6.837",
language = "English",
volume = "86",
pages = "837--845",
journal = "British Journal of Anaesthesia",
issn = "0007-0912",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Halothane potentiates the effect of methamphetamine and nomifensine on extracellular dopamine levels in rat striatum

T2 - A microdialysis study

AU - Adachi, Y. U.

AU - Watanabe, K.

AU - Satoh, T.

AU - Vízi, E.

PY - 2001

Y1 - 2001

N2 - Brain microdialysis was used to study the in vivo release and metabolism of dopamine (DA) in the rat striatum during halothane anaesthesia. Concentrations were measured in microdialysates collected every 20 min and applied directly to an on-line high-performance liquid chromatograph. Halothane was administered at concentrations of 0.5, 1.0, 1.5 and 2.0%. In another series of experiments, rats were treated intraperitoneally or locally with methamphetamine, a drug of abuse, or with nomifensine, a dopamine uptake blocker and antidepressant, in combination with 0.5 or 1.5% halothane. Halothane anaesthesia did not affect the dialysate (extracellular) concentration of DA at 2.0%. By contrast, the concentrations of DA metabolites [3-methoxytyramine (3-MT), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA)] increased during inhaled halothane anaesthesia in a dose-dependent manner and recovered after anaesthesia. Halothane potentiated the ability of methamphetamine to increase the extracellular concentration of DA when administered systemically, whereas only a small increase in DA accumulation was seen when methamphetamine was administered locally via the perfusate. Similarly, the increase in extracellular DA was accentuated by systemic nomifensine during halothane anaesthesia, but no obvious enhancement was observed when it was applied locally. It has been shown that the neurotoxic effect of methamphetamine is mediated by the suboxidation of DA released from the cytoplasm into the extracellular space and transformed into highly reactive free radicals. On the basis of our results, it is suggested that care should be exercised when halothane anaesthesia is used in patients abusing phenylethylamines (amphetamines) or being treated with DA uptake blockers (nomifensine).

AB - Brain microdialysis was used to study the in vivo release and metabolism of dopamine (DA) in the rat striatum during halothane anaesthesia. Concentrations were measured in microdialysates collected every 20 min and applied directly to an on-line high-performance liquid chromatograph. Halothane was administered at concentrations of 0.5, 1.0, 1.5 and 2.0%. In another series of experiments, rats were treated intraperitoneally or locally with methamphetamine, a drug of abuse, or with nomifensine, a dopamine uptake blocker and antidepressant, in combination with 0.5 or 1.5% halothane. Halothane anaesthesia did not affect the dialysate (extracellular) concentration of DA at 2.0%. By contrast, the concentrations of DA metabolites [3-methoxytyramine (3-MT), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA)] increased during inhaled halothane anaesthesia in a dose-dependent manner and recovered after anaesthesia. Halothane potentiated the ability of methamphetamine to increase the extracellular concentration of DA when administered systemically, whereas only a small increase in DA accumulation was seen when methamphetamine was administered locally via the perfusate. Similarly, the increase in extracellular DA was accentuated by systemic nomifensine during halothane anaesthesia, but no obvious enhancement was observed when it was applied locally. It has been shown that the neurotoxic effect of methamphetamine is mediated by the suboxidation of DA released from the cytoplasm into the extracellular space and transformed into highly reactive free radicals. On the basis of our results, it is suggested that care should be exercised when halothane anaesthesia is used in patients abusing phenylethylamines (amphetamines) or being treated with DA uptake blockers (nomifensine).

KW - Anaesthetics volatile, halothane

KW - Analeptics, methamphetamine

KW - Ataractics, nomifensine

KW - Brain striatum

KW - Brain, dopamine release

UR - http://www.scopus.com/inward/record.url?scp=0034993469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034993469&partnerID=8YFLogxK

U2 - 10.1093/bja/86.6.837

DO - 10.1093/bja/86.6.837

M3 - Article

VL - 86

SP - 837

EP - 845

JO - British Journal of Anaesthesia

JF - British Journal of Anaesthesia

SN - 0007-0912

IS - 6

ER -